Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

Pfizer is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist ...

Havas Health has appointed Anna Maria Marra as CEO of Europe to lead and oversee all aspects of the region's business ...

Recently, Pfizer has launched a specialised centre at a hospital in Gurugram and is planning to start more such centres to ...

Findings highlight the Pfizer-BioNTech vaccine’s role in preventing MIS-C, a rare post-COVID inflammatory syndrome in ...

GSK is the fifth company to leave BIO in roughly a year, a group that includes Pfizer (PFE). The departures coincided with a drop in lobbying spending from the group and other challenges, STAT says.

More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

Trump’s newly named WH chief of staff Susie Wiles retained her position as co-chair of the lobbying firm Mercury Public ...

Trump’s social media company, Trump Media and Technology Group, rose by 6 percent, beating an already hot market. This jump ...